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The Thoratec VAD has been used in a small number of children
according to the manufacturer’s database. As of May 2003, the
Thoratec VAD had been used as a bridge to transplant in the
United States in 8 children weighing less than 30 kg, but it had not
been used in any children as a bridge to recovery. The smallest
child was 17 kg.5 Unlike extracorporeal membrane oxygenation,
during the period of VAD support patients can be extubated and
ambulate, allowing rehabilitation. There is no single solution for
pediatric patients requiring mechanical support, but carefully se-
lected pediatric patients may benefit from the Thoratec device as a
bridge to transplant recovery. The current case demonstrates that,
even in a relatively small child, the device can be removed without
adverse effects on ventricular function despite apical cannulation.
References
1. Duncan B. Mechanical circulatory support for infants and children with
cardiac disease. Ann Thorac Surg. 2002;73:1670-7.
2. Reinhartz O, Stiller B, Eilers R, Farrar DJ. Current clinical status of
pulsatile pediatric circulatory support. ASAIO J. 2002;48:455-9.
3. Reinhartz O, Keith FM, El-Banayosy A, McBride LR, Robbins RC,
Copeland JG, et al. Multicenter experience with the Thoratec ventricular
assist device in children and adolescents. J Heart Lung Transplant.
2001;20:439-48.
4. Williams MR, Oz MC. Indications and patient selection for mechanical
ventricular assistance. Ann Thorac Surg. 2001;71:S86-91.
5. Copeland JG, Arabia FA, Smith RG. Bridge to transplantation with a
Thoratec left ventricular assist device in a 17 kg child. Ann Thorac Surg.
2001;71:1003-4.
The bovine jugular vein conduit for right ventricular outflow tract
reconstruction: A feasible alternative to homograft conduits?
Tomaso Bottio, MD, PhD,a Gaetano Thiene, MD,b Vladimiro Vida, MD,a Mila Della Barbera, MD,b Annalisa Angelini, MD,b
Giovanni Stellin, MD,a and Gino Gerosa, MD,a Padua, Italy
The bovine jugular vein conduit (BJVC) has been pro-posed for use in cardiac surgery for correction of con-genital heart defects, either for right ventricular outflowtract (RVOT) reconstruction1 or total cavopulmonary
anastomosis completion in Fontan circulation.2 Short-term and
midterm results with the BJVC are controversial: satisfactory
when used for RVOT reconstruction but rather disappointing for
Fontan completion. In this study we report our early and late
clinical results with BJVCs implanted in infants and children for
RVOT reconstruction.
Clinical Summary
Between June 1999 and December 2002, 10 patients (7 male and
3 female patients) with a median age of 2 months (mean age, 13.7
 25.1 months) underwent surgical repair of congenital heart
defects, including reconstruction of the RVOT with a BJVC (Con-
tegra; Medtronic, Inc, Minneapolis, Minn).
Patient demographics are detailed in Table 1.3 Truncus arteri-
osus was the indication in 5 patients (with right ventricular hyp-
oplasia in 1 patient), tetralogy of Fallot with pulmonary atresia in
2 patients, aortic arch interruption type B with severe aortic ste-
nosis in 1 patient, double-outlet right ventricle with pulmonary
atresia in 1 patient, and aortic stenosis in 1 patient. Four patients
had undergone previous palliative procedures.
Results
There were 2 (20%) hospital deaths. One patient (patient 3) oper-
ated on for truncus arteriosus died suddenly on the 52nd postop-
erative day at home. The second patient (patient 5), who under-
went a Ross-Konno procedure and a mitral valvuloplasty for aortic
and mitral stenosis, died on the first postoperative day after an
airway suction procedure. A third patient (patient 8), a baby girl
operated on for truncus arteriosus type A-4 of Van Praagh classi-
fication, died of respiratory distress syndrome on the 20th postop-
erative day after extracorporeal membrane oxygenator assistance.
Postmortem examination was performed in patients 3 and 5.
The remaining 7 patients were alive at the last follow-up.
Echocardiographic data, recorded after a median time of 25
months (mean time, 24.3  14 months), showed trivial incompe-
tence of the BJVC in 3 patients and moderate incompetence in 1
patient. A transvalvular vein conduit peak gradient of greater than
30 mm Hg was observed in 2 patients. In 1 patient a peak gradient
of greater than 30 mm Hg was detected at the level of the distal
anastomosis between the conduit and the left pulmonary artery.
Morphologic investigation was performed in an unimplanted
conduit that served as a control (Figure 1) and in the 2 conduits
explanted at autopsy (Figure 2).
The unimplanted conduit showed a well-fixed tissue with leaf-
lets consisting of a compact layer of collagen (fibrosa) and a layer
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Figure 1. A, Control Contegra conduit: gross view of the bovine jugular vein with cusps in the native position. B,
Histology of a leaflet and the vein wall (Weigert-Van Gieson staining). C, Close-up of the cusp, which mostly
consists of collagen with loose elastic fibers (Weigert-Van Gieson staining). D, Close-up of the vein wall: note the
parallel elastic lamellae orientation in the tunica media (Weigert-Van Gieson staining).
Figure 2. A, Contegra conduit in place for 52 days: gross view of the conduit at valve level explanted at autopsy.
Note the fibrous sheeting and a nodular calcific deposit close to the commissure (arrow). B, Histology of the
nodular extrinsic calcification located at the free margin of the leaflet (hematoxylin and eosin staining). C, Calcium
shells detached from the sinus side of the leaflets. D, Histology of the shells disclosing calcific deposits within the
fibrous sheet (hematoxylin and eosin staining).
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of loose elastic fibers on the lumen side, with no evidence of
spongiosa in between.
An endothelial lining was present on both sides. The vein wall
showed a tunica media mostly consisting of parallel-oriented elas-
tic lamellae, including smooth muscle cells and collagen fibers in
between. The latter were quite prominent at the basal cuspal
attachment. The adventitia exhibited scanty collagen and elastic
fibers, loose extracellular matrix, and small vessels.
The explant in place at day 1 (patient 5) from a patient who
died as a result of residual endocardial fibroelastosis, mitral ste-
nosis, and pulmonary hypertension showed intact bovine vein
cusps at gross examination and a thin fibrinous lining of both
leaflet sides at histology caused by the endothelial detachment,
with an otherwise intact vein wall.
The explant in place at days 52 (patient 3) from a patient who died
suddenly at home with pulmonary edema most probably caused by a
dysplastic incompetent truncal valve showed, to the naked eye, shells
of calcium deposit on the leaflets within the sinuses, with a pinpoint
calcification in the free margin close to a commissure. The shells,
detached from the leaflets, were confirmed to be mineral deposits at
radiography, which at histology appeared to occur within fibrous
tissue. Von Kossa stain disclosed the calcific nature of mineralization
extrinsic to the leaflet. Mild inflammatory infiltrates were observed in
the subendothelium of the vein wall, as well as in the adventitia, with
rare foreign body giant cells.
Discussion
The limited availability of homografts has forced surgeons to
search for alternative tissue valved conduits for RVOT reconstruc-
tion. The BJVC (Contegra) is a glutaraldeyde-treated xenograft
recently introduced on the market. Ichikawa and colleagues4 re-
ported excellent clinical results showing good tissue preservation,
but on the other hand, Chang and associates5 observed an inflam-
matory reaction involving either the leaflets or the conduit wall in
BJVCs implanted in an animal model. Breymann and coworkers6
reported a 27-month complete freedom from structural conduit
deterioration, suggesting that the Contegra conduit might represent
a promising alternative to homografts.
A report from Bove´ and colleagues1 recently supported these
findings. In their experience 41 patients with a mean age of 1.9
years who underwent RVOT reconstruction with a Contegra con-
duit showed satisfactory results, with excellent hemodynamic per-
formances favorably comparable with those of pulmonary ho-
mografts. The major limit of the study was the shortness of
follow-up. In their series they described one perioperative death
but without further data on postmortem examination of the ex-
planted conduit.
More recently, Schoof and associates2 discouraged the BJVC
use because of the catastrophic results obtained with such conduits
when used for completion of the Fontan circulation. The authors’
TABLE 1. Patient demographics
Patient
no.
Sex/age
at operation Native pathology Previous procedures
1 M/2 mo Tetralogy of Fallot, absent pulmonary valve No
2 F/12 mo Aortic arch interruption type B, subaortic
stenosis, VSD
Damus-Kaye Stensel procedure, modified B-T
shunt
3 M/20 d Truncus arteriosus, dysplastic truncal
valve incompetence, patent ductus
arteriosus
No
4 M/28 d Truncus arteriosus, truncal valve
incompetence, patent ductus arteriosus
No
5 M/5 mo Aortic and mitral stenosis, left ventricular
fibroelastosis
Percutaneous aortic valve plasty, surgical
closure of right atrium-aorta iatrogenic
communication
6 F/3 y Truncus arteriosus, right ventricular
hypoplasia
Cavopulmonary anastomosis, separation of
the great arteries, modified B-T shunt
7 M/2 mo Tetralogy of Fallot, pulmonary atresia,
major aortic-pulmonary collateral
arteries
RVOT reconstruction with a cryopreserved
homograft, 8 mm; unifocalization of 2
collateral arteries at the right pulmonary ilum
8 F/10 d Truncus arteriosus type A-4 of Van Praagh,
truncal valve incompetence, aortic arch
interruption, large PDA, ASD, VSD
No
9 M/10 d Truncus arteriosus type 1–2, truncal valve
incompetence, VSD, ASD
No
10 M/6 y Double-outlet right ventricle, pulmonary
atresia
B-T shunt, right pulmonary artery plasty
VSD, Ventricular septal defect; RVOT, right ventricular outflow tract; B-T, Blalock-Taussig; PTFE, polytetrafluoroethylene; PDA, patent ductus arteriousus;
ASD, atrial septal defect.
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hypothesis was that glutaraldehyde cytotoxicity might be respon-
sible for the high propensity for thrombosis by preventing the
endothelial lining of the conduit. Moreover, they suggest that the
cause of conduit thrombosis is the vein wall inflammatory reaction
attributed to glutaraldehyde cytotoxicity, which is a more danger-
ous and proaggregating factor when in slow and nonpulsatile flow,
as well as in Fontan circulation.
Our strategy was to use the Contegra conduit only in neonates
and young infants (median age, 2 months).
In 9 of these patients, the implanted Contegra conduit was 4
mm larger than the expected normal pulmonary valve orifice,
according to body surface area.3 The 6-year-old patient, who
received a 14-mm conduit, was affected by a severe pulmonary
artery stenosis at the time of the operation, and therefore he also
underwent a pulmonary artery plasty procedure. In this patient the
plasty procedure was expected to be palliative, waiting for subse-
quent pulmonary artery diameter growth. In this way, at the time
of that procedure, we decided not to use an oversized conduit
because of the limitation of forward flow mostly as a result of
pulmonary artery stenosis. To avoid larger right ventricular inci-
sion and therefore the unavoidable right ventricular failure, dila-
tion, and geometric distortion, we usually prefer to use conduits
that are not excessively oversized, reducing the right ventricular
length incisions.
In conclusion, use of the BJVC was preferred to use of the
homograft for RVOT reconstruction when its outgrowth was ex-
pected to anticipate structural degeneration. Unfortunately, the
evidence of calcium deposits as early as 52 days after implantation
in our postmortem specimens, which most probably occurred on
thrombus deposits on fibrous sheets, prompted us to reconsider the
pulmonary homograft as the conduit of choice.
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Surgical procedure/date
Normal pulmonary
valve orifice (mm)3 Outcome Conduit pathology
VSD closure, RVOT reconstruction with Contegra,
12 mm; 6/10/1999
8 Alive
B-T shunt takedown, tunnel left ventricle-pulmonary
artery with PTFE patch, RVOT reconstruction with
Contegra 14, 9/12/1999
10.1 Alive
VSD closure, RVOT reconstruction with Contegra,
12 mm; 2/29/2000
8 Died (52 d
postoperatively)
Extrinsic calcification on fibrous
tissue overgrowth
VSD closure, RVOT reconstruction with Contegra,
12 mm; 3/21/2000
8 Alive
Ross-Konno operation; mitral valve plasty; RVOT
reconstruction with Contegra, 12 mm; 5/16/2000
8.5 Died (1 d
postoperatively)
Intact conduit, cusp fibrinous
lining
One-and-a-half ventricle repair; VSD closure; RVOT
reconstruction with Contegra, 16 mm; 9/19/2000
12.5 Alive
VSD closure; left pulmonary artery plasty; RVOT
reconstruction with a Contegra, 18 mm; 9/26/2000
12 Alive
VSD closure; RVOT reconstruction with Contegra,
12 mm; 11/9/2000
8 Died (20 d
postoperatively)
Autopsy not performed
VSD closure; RVOT reconstruction with Contegra,
12 mm; 6/5/2002
8 Alive
B-T shunt take down; right and left pulmonary
artery plasty; VSD closure; RVOT reconstruction
with Contegra, 14 mm; 6/20/2002
14 Alive
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